ciprofloxacin has been researched along with Cholera in 45 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Cholera: An acute diarrheal disease endemic in India and Southeast Asia whose causative agent is VIBRIO CHOLERAE. This condition can lead to severe dehydration in a matter of hours unless quickly treated.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the clinical and bacteriological success of single dose treatment with azithromycin and ciprofloxacin in children with cholera." | 9.14 | Single dose azithromycin versus ciprofloxacin for cholera in children: a randomized controlled trial. ( Das, S; Faridi, MM; Gupta, P; Kaushik, JS, 2010) |
| "We conducted a randomized double-blinded study in Lima, Peru, to assess the tolerability and efficacy of a single 250-mg dose of ciprofloxacin in preventing diarrhea and Vibrio cholerae O1 infection among household contacts of bacteriologically confirmed index cases." | 9.08 | Efficacy and tolerability of ciprofloxacin prophylaxis in adult household contacts of patients with cholera. ( Carrillo, C; Echevarría, J; Gotuzzo, E; Mostorino, R; Ruiz, R; Seas, C, 1995) |
| "We conducted a randomized, double-blind clinical trial to compare ciprofloxacin (250 mg once a day for 3 days) with tetracycline (500 mg four times a day for 3 days) in terms of efficacy and safety in the treatment of moderate-to-severe cholera in Peruvian adults." | 9.08 | Ciprofloxacin for the treatment of cholera: a randomized, double-blind, controlled clinical trial of a single daily dose in Peruvian adults. ( Carrillo, C; Echevarría, J; Gotuzzo, E; Mostorino, R; Ruiz, R; Seas, C, 1995) |
| "Among patients infected with V cholerae 01, treatment was clinically successful in 62 (94%) of 66 patients who received ciprofloxacin and in 47 (73%) of 64 who receive doxycycline (difference 21% [95% Cl 8-33]); the corresponding proportions with bacteriological success were 63 (95%) and 44 (69%) (27% [14-39])." | 9.08 | Randomised controlled comparison of single-dose ciprofloxacin and doxycycline for cholera caused by Vibrio cholerae 01 or 0139. ( Bennish, ML; Busch, W; Dhar, U; Khan, EH; Khan, WA; Ronan, A; Salam, MA; Seas, C, 1996) |
| "To explore the efficacy of single dose ciprofloxacin therapy in cholera, a randomized, open, controlled clinical trial was carried out." | 9.08 | Single dose ciprofloxacin in cholera. ( Ağalar, C; Diri, C; Türkyilmaz, R; Usubütün, S, 1997) |
| "We identified a poor clinical response to treatment of cholera with a single 1 g dose of ciprofloxacin, a standard treatment for cholera." | 7.81 | Efficacy of Ciprofloxacin for Treatment of Cholera Associated with Diminished Susceptibility to Ciprofloxacin to Vibrio cholerae O1. ( Ahmed, S; Bennish, ML; Khan, WA; Saha, D; Salam, MA, 2015) |
| "Vibrio cholerae O1 biotype El Tor producing Haitian variant Cholera Toxin (HCT) and showing reduced susceptibility to ciprofloxacin caused a cholera outbreak associated with a high case fatality rate (4." | 7.80 | Haitian variant ctxB producing Vibrio cholerae O1 with reduced susceptibility to ciprofloxacin is persistent in Yavatmal, Maharashtra, India, after causing a cholera outbreak. ( Deshmukh, DG; Ingole, KV; Jain, M; Kumar, P; Mishra, DK; Yadava, PK; Zade, AM, 2014) |
| "We determined the in vitro antibacterial activity of ciprofloxacin against Vibrio cholerae O139 recently isolated from cholera patients in India." | 7.74 | Antibacterial activity of ciprofloxacin against clinical strains of Vibrio cholerae O139 recently isolated from India. ( Okuda, J; Ramamurthy, T; Yamasaki, S, 2007) |
| "Ciprofloxacin was used for DFA-DVC as V." | 5.37 | Demonstration of viable but nonculturable Vibrio cholerae O1 in fresh water environment of India using ciprofloxacin DFA-DVC method. ( Mishra, A; Sharma, M; Taneja, N, 2011) |
| " cholera were as follows 76% [67,84] to furazolidone, 65% [29,94] to nitrofurantoin, 55% [44,66] to nalidixic acid, 10% [2,23] to rifampicin, 4%(0, 12) to novobiocin, 4% [2,6] to norfloxacin, 3% [1,4] to ciprofloxacin, 1%(0, 3) to sparofloxacin, 0%(0, 3) to levofloxacin, 0%(0, 2) to ofloxacin, 0%(0, 0) to gatifloxacin." | 5.22 | Globally Vibrio cholera antibiotics resistance to RNA and DNA effective antibiotics: A systematic review and meta-analysis. ( Ebrahimzadeh, F; Gholami, S; Jafari-Sales, A; Rostami, A; Zadeh, FA, 2022) |
| "To compare the clinical and bacteriological success of single dose treatment with azithromycin and ciprofloxacin in children with cholera." | 5.14 | Single dose azithromycin versus ciprofloxacin for cholera in children: a randomized controlled trial. ( Das, S; Faridi, MM; Gupta, P; Kaushik, JS, 2010) |
| "We conducted a double-blind, randomized trial comparing the equivalence of azithromycin and ciprofloxacin (each given in a single 1-g dose of two 500-mg tablets) among 195 men with severe cholera caused by Vibrio cholerae O1 or O139." | 5.12 | Single-dose azithromycin for the treatment of cholera in adults. ( Ahmed, S; Bennish, ML; Karim, MM; Khan, WA; Saha, D; Salam, MA, 2006) |
| "We conducted a randomized double-blinded study in Lima, Peru, to assess the tolerability and efficacy of a single 250-mg dose of ciprofloxacin in preventing diarrhea and Vibrio cholerae O1 infection among household contacts of bacteriologically confirmed index cases." | 5.08 | Efficacy and tolerability of ciprofloxacin prophylaxis in adult household contacts of patients with cholera. ( Carrillo, C; Echevarría, J; Gotuzzo, E; Mostorino, R; Ruiz, R; Seas, C, 1995) |
| "We conducted a randomized, double-blind clinical trial to compare ciprofloxacin (250 mg once a day for 3 days) with tetracycline (500 mg four times a day for 3 days) in terms of efficacy and safety in the treatment of moderate-to-severe cholera in Peruvian adults." | 5.08 | Ciprofloxacin for the treatment of cholera: a randomized, double-blind, controlled clinical trial of a single daily dose in Peruvian adults. ( Carrillo, C; Echevarría, J; Gotuzzo, E; Mostorino, R; Ruiz, R; Seas, C, 1995) |
| "Among patients infected with V cholerae 01, treatment was clinically successful in 62 (94%) of 66 patients who received ciprofloxacin and in 47 (73%) of 64 who receive doxycycline (difference 21% [95% Cl 8-33]); the corresponding proportions with bacteriological success were 63 (95%) and 44 (69%) (27% [14-39])." | 5.08 | Randomised controlled comparison of single-dose ciprofloxacin and doxycycline for cholera caused by Vibrio cholerae 01 or 0139. ( Bennish, ML; Busch, W; Dhar, U; Khan, EH; Khan, WA; Ronan, A; Salam, MA; Seas, C, 1996) |
| "To explore the efficacy of single dose ciprofloxacin therapy in cholera, a randomized, open, controlled clinical trial was carried out." | 5.08 | Single dose ciprofloxacin in cholera. ( Ağalar, C; Diri, C; Türkyilmaz, R; Usubütün, S, 1997) |
| "We identified a poor clinical response to treatment of cholera with a single 1 g dose of ciprofloxacin, a standard treatment for cholera." | 3.81 | Efficacy of Ciprofloxacin for Treatment of Cholera Associated with Diminished Susceptibility to Ciprofloxacin to Vibrio cholerae O1. ( Ahmed, S; Bennish, ML; Khan, WA; Saha, D; Salam, MA, 2015) |
| "Vibrio cholerae O1 biotype El Tor producing Haitian variant Cholera Toxin (HCT) and showing reduced susceptibility to ciprofloxacin caused a cholera outbreak associated with a high case fatality rate (4." | 3.80 | Haitian variant ctxB producing Vibrio cholerae O1 with reduced susceptibility to ciprofloxacin is persistent in Yavatmal, Maharashtra, India, after causing a cholera outbreak. ( Deshmukh, DG; Ingole, KV; Jain, M; Kumar, P; Mishra, DK; Yadava, PK; Zade, AM, 2014) |
| " cholerae especially towards ciprofloxacin may significantly influence the control strategies in future outbreaks." | 3.75 | Epidemiology & antibiograms of Vibrio cholerae isolates from a tertiary care hospital in Chandigarh, north India. ( Chander, J; Deep, A; Gupta, V; Kaistha, N; Mehta, M; Sarkar, BL; Singla, N, 2009) |
| "We determined the in vitro antibacterial activity of ciprofloxacin against Vibrio cholerae O139 recently isolated from cholera patients in India." | 3.74 | Antibacterial activity of ciprofloxacin against clinical strains of Vibrio cholerae O139 recently isolated from India. ( Okuda, J; Ramamurthy, T; Yamasaki, S, 2007) |
| "Cholera has been endemic in Douala since 1971." | 1.40 | Water sources as reservoirs of Vibrio cholerae O1 and non-O1 strains in Bepanda, Douala (Cameroon): relationship between isolation and physico-chemical factors. ( Akoachere, JF; Mbuntcha, CK, 2014) |
| "Ciprofloxacin was used for DFA-DVC as V." | 1.37 | Demonstration of viable but nonculturable Vibrio cholerae O1 in fresh water environment of India using ciprofloxacin DFA-DVC method. ( Mishra, A; Sharma, M; Taneja, N, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (24.44) | 18.2507 |
| 2000's | 11 (24.44) | 29.6817 |
| 2010's | 17 (37.78) | 24.3611 |
| 2020's | 6 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Yuan, XH | 1 |
| Li, YM | 1 |
| Vaziri, AZ | 2 |
| Kaviar, VH | 1 |
| Jin, Y | 2 |
| Maleki, A | 2 |
| Omidi, N | 2 |
| Kouhsari, E | 2 |
| Rostami, A | 1 |
| Zadeh, FA | 1 |
| Ebrahimzadeh, F | 1 |
| Jafari-Sales, A | 1 |
| Gholami, S | 1 |
| Wu, Q | 1 |
| Hassan Kaviar, V | 1 |
| Khadivar, P | 1 |
| Creasy-Marrazzo, A | 1 |
| Saber, MM | 1 |
| Kamat, M | 1 |
| Bailey, LS | 1 |
| Brinkley, L | 1 |
| Cato, E | 1 |
| Begum, Y | 1 |
| Rashid, MM | 1 |
| Khan, AI | 2 |
| Qadri, F | 1 |
| Basso, KB | 1 |
| Shapiro, BJ | 1 |
| Nelson, EJ | 1 |
| Mohanraj, RS | 1 |
| Samanta, P | 1 |
| Mukhopadhyay, AK | 2 |
| Mandal, J | 1 |
| Amicizia, D | 1 |
| Micale, RT | 1 |
| Pennati, BM | 1 |
| Zangrillo, F | 1 |
| Iovine, M | 1 |
| Lecini, E | 1 |
| Marchini, F | 1 |
| Lai, PL | 1 |
| Panatto, D | 1 |
| Parvin, I | 1 |
| Shahunja, KM | 1 |
| Khan, SH | 1 |
| Alam, T | 1 |
| Shahrin, L | 1 |
| Ackhter, MM | 1 |
| Sarmin, M | 1 |
| Dash, S | 1 |
| Rahman, MW | 1 |
| Shahid, ASMSB | 1 |
| Golam Faruque, AS | 1 |
| Ahmed, T | 1 |
| Chisti, MJ | 1 |
| Kumar, P | 2 |
| Yadav, P | 1 |
| Deshmukh, DG | 2 |
| Bulle, PA | 1 |
| Singh, D | 1 |
| Singh, N | 1 |
| Sharma, KK | 1 |
| Jain, M | 2 |
| Ingole, KV | 2 |
| Goel, AK | 1 |
| Yadava, PK | 2 |
| Mohan, B | 1 |
| Sethuraman, N | 1 |
| Verma, R | 1 |
| Taneja, N | 3 |
| van Zwetselaar, M | 1 |
| Nyombi, B | 1 |
| Sonda, T | 1 |
| Kumburu, H | 1 |
| Chamba, N | 1 |
| Dekker, MCJ | 1 |
| Kilonzo, KG | 1 |
| Urasa, SJ | 1 |
| Mmbaga, BT | 1 |
| Mishra, DK | 1 |
| Zade, AM | 1 |
| Divya, MP | 1 |
| Sivakumar, KC | 1 |
| Sarada Devi, KL | 1 |
| Remadevi, S | 1 |
| Thomas, S | 1 |
| Akoachere, JF | 1 |
| Mbuntcha, CK | 1 |
| Mahmud, ZH | 1 |
| Islam, S | 1 |
| Zaman, RU | 1 |
| Akter, M | 1 |
| Talukder, KA | 1 |
| Bardhan, PK | 1 |
| Rhodes, FC | 1 |
| Kamara, A | 1 |
| Wurie, IM | 1 |
| Alemu, W | 1 |
| Jambai, A | 1 |
| Faruque, SM | 1 |
| Clemens, JD | 1 |
| Islam, MS | 1 |
| Khan, WA | 3 |
| Saha, D | 2 |
| Ahmed, S | 2 |
| Salam, MA | 3 |
| Bennish, ML | 3 |
| Lübbert, C | 1 |
| Mandal, S | 1 |
| Pal, NK | 1 |
| Chowdhury, IH | 1 |
| Debmandal, M | 1 |
| Kaushik, JS | 1 |
| Gupta, P | 1 |
| Faridi, MM | 1 |
| Das, S | 2 |
| Chander, J | 1 |
| Kaistha, N | 1 |
| Gupta, V | 1 |
| Mehta, M | 1 |
| Singla, N | 1 |
| Deep, A | 1 |
| Sarkar, BL | 1 |
| Quilici, ML | 1 |
| Massenet, D | 1 |
| Gake, B | 1 |
| Bwalki, B | 1 |
| Olson, DM | 1 |
| Chen, PY | 1 |
| Mu, JJ | 1 |
| Lin, HY | 1 |
| Li, KJ | 1 |
| Lee, PI | 1 |
| Hsueh, PR | 1 |
| Saidi, SM | 1 |
| Yamasaki, S | 2 |
| Lijima, Y | 1 |
| Kariuki, S | 1 |
| Mishra, A | 1 |
| Sharma, M | 2 |
| Cummings, MJ | 1 |
| Wamala, JF | 1 |
| Eyura, M | 1 |
| Malimbo, M | 1 |
| Omeke, ME | 1 |
| Mayer, D | 1 |
| Lukwago, L | 1 |
| Rashed, SM | 1 |
| Mannan, SB | 1 |
| Johura, FT | 1 |
| Islam, MT | 1 |
| Sadique, A | 1 |
| Watanabe, H | 1 |
| Sack, RB | 1 |
| Huq, A | 1 |
| Colwell, RR | 1 |
| Cravioto, A | 1 |
| Alam, M | 1 |
| Biswal, M | 1 |
| Tarai, B | 1 |
| Goyal, R | 1 |
| Ramachandran, VJ | 1 |
| Gupta, S | 1 |
| Krishna, BV | 1 |
| Patil, AB | 1 |
| Chandrasekhar, MR | 1 |
| Karim, MM | 1 |
| Pal, BB | 1 |
| Khuntia, HK | 1 |
| Samal, SK | 1 |
| Das, SS | 1 |
| Chhotray, GP | 1 |
| Chan, MR | 1 |
| Pirsch, JD | 1 |
| Okuda, J | 1 |
| Ramamurthy, T | 2 |
| Chatterjee, S | 1 |
| Ghosh, K | 1 |
| Raychoudhuri, A | 1 |
| Pan, A | 1 |
| Bhattacharya, MK | 2 |
| Bhattacharya, SK | 2 |
| Nandy, RK | 1 |
| Echevarría, J | 3 |
| Seas, C | 4 |
| Carrillo, C | 3 |
| Mostorino, R | 2 |
| Ruiz, R | 3 |
| Gotuzzo, E | 3 |
| Lange, KH | 1 |
| Pedersen, KM | 1 |
| Nielsen, SE | 1 |
| Høiby, N | 1 |
| Chakrabarti, MK | 1 |
| Sinha, AK | 1 |
| Chatterjee, DC | 1 |
| Doğanci, L | 1 |
| Gün, H | 1 |
| Baysallar, M | 1 |
| Albay, A | 1 |
| Cinar, E | 1 |
| Haznedaroğlu, T | 1 |
| Khan, EH | 1 |
| Ronan, A | 1 |
| Dhar, U | 1 |
| Busch, W | 1 |
| Maggi, P | 2 |
| Carbonara, S | 2 |
| Santantonio, T | 2 |
| Pastore, G | 2 |
| Angarano, G | 1 |
| Fico, C | 1 |
| Romanelli, C | 1 |
| Sforza, E | 1 |
| Usubütün, S | 1 |
| Ağalar, C | 1 |
| Diri, C | 1 |
| Türkyilmaz, R | 1 |
| Suankratay, C | 1 |
| Phantumchinda, K | 1 |
| Tachawiboonsak, W | 1 |
| Wilde, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparative Study of Commercially Available Typhoid Point of Care Tests to Benchmark Current and Emerging Tools[NCT04673487] | 2,000 participants (Anticipated) | Observational | 2021-01-31 | Not yet recruiting | |||
| Randomized, Double-Blind, Controlled Clinical Trial to Compare Efficacy of a Single Dose of Azithromycin Versus a Single Dose of Ciprofloxacin in the Treatment of Adults With Clinically Severe Cholera Due to V. Cholerae O1 or O139[NCT00229944] | Phase 3 | 220 participants | Interventional | 2002-12-31 | Completed | ||
| A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Two-Part Trial to Evaluate the Efficacy, Safety, and Tolerability of iOWH032 in the Treatment of Acute Dehydrating Diarrhea in Adult and Pediatric Patients With Cholera[NCT02111304] | Phase 2 | 0 participants (Actual) | Interventional | 2014-06-30 | Withdrawn (stopped due to Trial was never initiated due to PATH executive decision.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for ciprofloxacin and Cholera
| Article | Year |
|---|---|
Global status of antimicrobial resistance among environmental isolates of Vibrio cholerae O1/O139: a systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; Ceftriaxone; Cholera; Ciprofloxacin; Doxycycline; Drug Resistance, Bacterial; | 2022 |
Globally Vibrio cholera antibiotics resistance to RNA and DNA effective antibiotics: A systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; Cephalothin; Cholera; Cholera Toxin; Ciprofloxacin; Drug Resistance, Bacteria | 2022 |
Antimicrobial resistance among clinical
Topics: Anti-Bacterial Agents; Chloramphenicol; Cholera; Ciprofloxacin; Drug Resistance, Bacterial; Erythrom | 2023 |
Burden of typhoid fever and cholera: similarities and differences. Prevention strategies for European travelers to endemic/epidemic areas.
Topics: Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Azithromycin; Bicarbonates; C | 2019 |
Antimicrobial therapy of acute diarrhoea: a clinical review.
Topics: Acute Disease; Aminoglycosides; Anti-Bacterial Agents; Azithromycin; Bacterial Infections; Campyloba | 2016 |
7 trials available for ciprofloxacin and Cholera
| Article | Year |
|---|---|
Single dose azithromycin versus ciprofloxacin for cholera in children: a randomized controlled trial.
Topics: Azithromycin; Child; Child, Preschool; Cholera; Ciprofloxacin; Humans; Treatment Failure; Vibrio cho | 2010 |
Single-dose azithromycin for the treatment of cholera in adults.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Bangladesh; Cholera; Ciprofloxacin; Combined Modality Th | 2006 |
Single-dose azithromycin for the treatment of cholera in adults.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Bangladesh; Cholera; Ciprofloxacin; Combined Modality Th | 2006 |
Single-dose azithromycin for the treatment of cholera in adults.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Bangladesh; Cholera; Ciprofloxacin; Combined Modality Th | 2006 |
Single-dose azithromycin for the treatment of cholera in adults.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Bangladesh; Cholera; Ciprofloxacin; Combined Modality Th | 2006 |
Efficacy and tolerability of ciprofloxacin prophylaxis in adult household contacts of patients with cholera.
Topics: Administration, Oral; Adolescent; Adult; Aged; Cholera; Ciprofloxacin; Diarrhea; Double-Blind Method | 1995 |
Ciprofloxacin for the treatment of cholera: a randomized, double-blind, controlled clinical trial of a single daily dose in Peruvian adults.
Topics: Administration, Oral; Adolescent; Adult; Aged; Cholera; Ciprofloxacin; Double-Blind Method; Drug Adm | 1995 |
Oral ciprofloxacin in the treatment of cholera.
Topics: Adolescent; Adult; Anti-Infective Agents; Cholera; Ciprofloxacin; Disease Outbreaks; Double-Blind Me | 1995 |
Randomised controlled comparison of single-dose ciprofloxacin and doxycycline for cholera caused by Vibrio cholerae 01 or 0139.
Topics: Administration, Oral; Adult; Cholera; Ciprofloxacin; Double-Blind Method; Doxycycline; Humans; Male; | 1996 |
Single dose ciprofloxacin in cholera.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Cholera; Ciprofloxacin; Doxyc | 1997 |
33 other studies available for ciprofloxacin and Cholera
| Article | Year |
|---|---|
Genome-wide association studies reveal distinct genetic correlates and increased heritability of antimicrobial resistance in
Topics: Anaerobiosis; Anti-Bacterial Agents; Azithromycin; Cholera; Ciprofloxacin; Doxycycline; Drug Resista | 2022 |
Haitian-like genetic traits with creeping MIC of Azithromycin in
Topics: Alleles; Anti-Bacterial Agents; Azithromycin; Cholera; Ciprofloxacin; Drug Resistance, Bacterial; Fe | 2020 |
Changing Susceptibility Pattern of
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Bangladesh; Child; Cholera; Ciprofloxacin; Drug Resistan | 2020 |
Vibrio cholerae O1 with ctxB7 variant genotype acquired qnrVC mediated ciprofloxacin resistance in Yavatmal, India.
Topics: Anti-Bacterial Agents; Cholera; Cholera Toxin; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug | 2017 |
Speciation, clinical profile & antibiotic resistance in
Topics: Adolescent; Adult; Aeromonas; Cefotaxime; Child; Child, Preschool; Cholera; Ciprofloxacin; Diarrhea; | 2017 |
Aeromonas caviae mimicking Vibrio cholerae infectious enteropathy in a cholera-endemic region with possible public health consequences: two case reports.
Topics: Acetaminophen; Adult; Aeromonas caviae; Anti-Bacterial Agents; Cholera; Ciprofloxacin; Diagnosis, Di | 2018 |
Haitian variant ctxB producing Vibrio cholerae O1 with reduced susceptibility to ciprofloxacin is persistent in Yavatmal, Maharashtra, India, after causing a cholera outbreak.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Cholera; Cholera Toxin; Ciprofloxacin; Disease Outbreaks; | 2014 |
Novel multiple mutations in the topoisomerase gene of Haitian variant Vibrio cholerae O1.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Base Sequence; Cholera; Cholera Toxin; Ciprofloxacin; DN | 2014 |
Water sources as reservoirs of Vibrio cholerae O1 and non-O1 strains in Bepanda, Douala (Cameroon): relationship between isolation and physico-chemical factors.
Topics: Anti-Bacterial Agents; Cameroon; Cholera; Ciprofloxacin; Disease Reservoirs; Humans; Rivers; Seasons | 2014 |
Phenotypic and genotypic characteristics of Vibrio cholerae O1 isolated from the Sierra Leone cholera outbreak in 2012.
Topics: Anti-Bacterial Agents; Azithromycin; Bacterial Typing Techniques; Cholera; Ciprofloxacin; Disease Ou | 2014 |
Efficacy of Ciprofloxacin for Treatment of Cholera Associated with Diminished Susceptibility to Ciprofloxacin to Vibrio cholerae O1.
Topics: Bangladesh; Cholera; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fe | 2015 |
Antibacterial activity of ciprofloxacin and trimethoprim, alone and in combinittion, against Vibrio cholerae O1 biotype El Tor serotype Ogawa isolates.
Topics: Anti-Infective Agents, Urinary; Cholera; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Drug T | 2009 |
Epidemiology & antibiograms of Vibrio cholerae isolates from a tertiary care hospital in Chandigarh, north India.
Topics: Age Factors; Amoxicillin; Anti-Bacterial Agents; Cefotaxime; Cholera; Ciprofloxacin; Drug Resistance | 2009 |
Vibrio cholerae O1 variant with reduced susceptibility to ciprofloxacin, Western Africa.
Topics: Anti-Bacterial Agents; Cholera; Cholera Toxin; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; | 2010 |
Vibrio cholerae O1 infection in Taiwan.
Topics: Base Sequence; Cholera; Ciprofloxacin; Disease Notification; Foodborne Diseases; Humans; Immunocompr | 2011 |
Cholera-like diarrhoea due to Salmonella infection.
Topics: Anti-Bacterial Agents; Cholera; Ciprofloxacin; Humans; Kenya; Male; Middle Aged; Salmonella; Salmone | 2011 |
Demonstration of viable but nonculturable Vibrio cholerae O1 in fresh water environment of India using ciprofloxacin DFA-DVC method.
Topics: Bacteriological Techniques; Cholera; Ciprofloxacin; Fluorescence; Fresh Water; India; Vibrio cholera | 2011 |
A cholera outbreak among semi-nomadic pastoralists in northeastern Uganda: epidemiology and interventions.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Child; Child, Preschool; Cholera; | 2012 |
Genetic characteristics of drug-resistant Vibrio cholerae O1 causing endemic cholera in Dhaka, 2006-2011.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Typing Techniques; Bangladesh; Base Sequence; | 2012 |
Emergence of Vibrio cholerae O1 Biotype El Tor serotype Inaba in north India.
Topics: Adolescent; Adult; Aged; Amikacin; Anti-Infective Agents; Cefotaxime; Child; Child, Preschool; Chole | 2005 |
Fluoroquinolone resistance in Vibrio cholerae O1: emergence of El Tor Inaba.
Topics: Acute Disease; Anti-Infective Agents; Child; Cholera; Ciprofloxacin; Drug Resistance, Bacterial; Hum | 2005 |
Fluoroquinolone-resistant Vibrio cholerae isolated during a cholera outbreak in India.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Child; Child, Preschool; Cholera; Ciprofloxacin; Dis | 2006 |
Emergence of Vibrio cholerae O1 biotype El Tor serotype Inaba causing outbreaks of cholera in Orissa, India.
Topics: Cholera; Ciprofloxacin; Diarrhea; Disease Outbreaks; Female; Humans; India; Male; Microbial Sensitiv | 2006 |
Nonserogroup O1 Vibrio cholerae in a renal transplant patient.
Topics: Adult; Anti-Bacterial Agents; Ceftriaxone; Cholera; Ciprofloxacin; Humans; Kidney Transplantation; M | 2007 |
Antibacterial activity of ciprofloxacin against clinical strains of Vibrio cholerae O139 recently isolated from India.
Topics: Anti-Bacterial Agents; Cholera; Ciprofloxacin; Drug Resistance, Bacterial; Humans; India; Vibrio cho | 2007 |
Phenotypic and genotypic traits and epidemiological implication of Vibrio cholerae O1 and O139 strains in India during 2003.
Topics: Anti-Bacterial Agents; Cholera; Ciprofloxacin; Cluster Analysis; DNA Fingerprinting; DNA, Bacterial; | 2007 |
[Cholera in Denmark--an imported case of illness].
Topics: Cholera; Ciprofloxacin; Denmark; Female; Humans; Middle Aged; Pacific Islands; Travel | 1995 |
Evaluation of the efficacy of different antibiotics in inhibiting colonisation of Vibrio cholerae O1 in the rabbit intestine.
Topics: Animals; Anti-Bacterial Agents; Cholera; Ciprofloxacin; Disease Models, Animal; Evaluation Studies a | 1993 |
Short-term quinolones for successful eradication of multiply resistant Vibrio cholerae in adult patients.
Topics: Adult; Anti-Infective Agents; Cholera; Ciprofloxacin; Drug Resistance, Microbial; Drug Resistance, M | 1995 |
Ciprofloxacin for treating cholera.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Cholera; Ciprofloxacin; Disease Outbreaks; Dr | 1996 |
Epidemiological, clinical and therapeutic evaluation of the Italian cholera epidemic in 1994.
Topics: Adult; Aged; Anti-Infective Agents; Cholera; Ciprofloxacin; Disease Outbreaks; Drug Resistance, Micr | 1997 |
Advice for travelers.
Topics: Anti-Infective Agents; Antidiarrheals; Bacterial Vaccines; Cholera; Ciprofloxacin; Diarrhea; Diphthe | 1998 |
Non-serogroup O:1 Vibrio cholerae bacteremia and cerebritis.
Topics: Adult; Anti-Infective Agents; Bacteremia; Cefotaxime; Cephalosporins; Cholera; Ciprofloxacin; Humans | 2001 |